Multispan Announces Co-Marketing Plan with Molecular Devices Corporation
27 September 2006 - 3:54AM
PR Newswire (US)
HAYWARD, Calif., Sept. 26 /PRNewswire/ -- Multispan Inc., a
technology platform company specializing in G-Protein-Coupled
Receptor (GPCR) research, today announced the launch of a series of
co-marketing campaigns with Molecular Devices Corp. (NASDAQ:MDCC),
the leading manufacturer of instrumentation and reagents for GPCR
research. Multispan and Molecular Devices have recently completed
an intensive evaluation of Molecular Devices' latest product for
GPCR screening, the FLIPR(R) Calcium 4 Assay Kit for GPCRs. The
evaluation consisted of utilizing Multispan's GPCR compound
profiling panel and GPCR stable cell-lines to compare the Ca++
detection of FLIPR Calcium 4 Assay Kit with competitor kits over 48
Multispan receptors. The results indicated that the FLIPR Calcium 4
Assay Kit had superior overall performance over the previous
Molecular Devices' FLIPR Calcium and Calcium 3 Assay Kits and those
from competitors. Under the terms of this co-marketing program,
Multispan has agreed to actively promote Molecular Devices'
FLIPR(R) Calcium 4 Assay Kit to its partners and customers, in
conjunction with Molecular Devices' promotion of Multispan's GPCR
compound profiling service and stable cell-line assays to its
customer base. Both companies will create literature and web links
to support the campaign. "Molecular Devices has been the product
leader and provider of instruments and reagents for GPCR drug
discovery over the past decade. Multispan's GPCR biological assay
platform shares great synergy with Molecular Devices products for
Ca++ detection," said Helena Mancebo, Chief Executive Officer at
Multispan. "We are thrilled to have them as a partner." About
Multispan: Multispan Inc. is a San Francisco Bay Area-based
biotechnology company focused exclusively on GPCRs, the most
important protein class of therapeutic targets. Privately held, and
founded in 2004, Multispan has created the industry's largest
collection of human GPCR expression clones and has engineered a
large collection of assays for GPCR drug screening with its
proprietary high expression technology for multi-trans-membrane
proteins. About Molecular Devices: Molecular Devices Corporation is
a leading supplier of high-performance bioanalytical measurement
systems that accelerate and improve drug discovery and other life
sciences research. The Company's systems and consumables enable
pharmaceutical and biotechnology companies to leverage advances in
genomics, proteomics and parallel chemistry to facilitate the
high-throughput and cost-effective identification and evaluation of
drug candidates. The Company's solutions are based on its advanced
core technologies that integrate its expertise in engineering,
molecular and cell biology and chemistry. Molecular Devices enables
its customers to improve research productivity and effectiveness,
which ultimately accelerates the complex process of discovering and
developing new drugs. For further information, please visit our
website (http://www.multispaninc.com/) or contact Helena Mancebo ()
DATASOURCE: Multispan Inc. CONTACT: Helena Mancebo, Ph.D.,
President and CEO of Multispan, Inc., +1-510-887-0817, ext 101, or
cell, +1-510-396-5452, or fax, +1-510-887-0863, or Web site:
http://www.multispaninc.com/
Copyright
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jan 2025 to Feb 2025
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Feb 2024 to Feb 2025
Real-Time news about Molecular Devices (MM) (NASDAQ): 0 recent articles
More Molecular Devices (MM) News Articles